Bayer to support development and supply of CVnCoV COVID-19 vaccine

Bayer has agreed to support the further development, supply and key territory operations of the CVnCoV COVID-19 vaccine candidate by signing a collaboration and services agreement with CureVac.

According to the enterprises, Bayer will facilitate this by contributing its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain performance and support in selected countries.

“The need for vaccines against COVID-19 is enormous. We are therefore pleased to be able to provide significant support to CureVac, a leader in mRNA technology, in advancing the further development and supply of its COVID-19 vaccine candidate,” said Stefan Oelrich, Member of the Board of Management at Bayer AG and President of the Bayer’s Pharmaceuticals Division. “We are highly committed to making our capabilities and networks available to help end this pandemic.”

“We are very happy to join forces with Bayer, whose expertise and infrastructure will help us make our vaccine candidate CVnCoV even more rapidly available to as many people as possible,” said Dr Franz-Werner Haas, Chief Executive Officer of CureVac. “Building on the positive data we have seen so far with CVnCoV, we now also have another strong partner on our side to get the vaccine to the people who need it following the receipt of the requisite regulatory approvals.”

Based on the collaboration agreement, CureVac will be the Marketing Authorization holder for the product, while Bayer will support CureVac with country operations within the European Union (EU) and selected additional markets. Under the agreement, Bayer holds further options to become Marketing Authorization holder in other markets outside of Europe.

CVnCoV is currently being investigated in a global Phase IIb/III trial.